NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Price Target & More

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) released its quarterly earnings results on Monday, March, 5th. The company reported ($0.80) EPS for the quarter, missing the Zacks' consensus estimate of ($0.76) by $0.04. The firm earned $1.19 million during the quarter, compared to the consensus estimate of $0.75 million. Syndax Pharmaceuticals had a negative net margin of 2,884.34% and a negative return on equity of 63.51%. Syndax Pharmaceuticals's revenue for the quarter was up 290.2% compared to the same quarter last year. View Syndax Pharmaceuticals' Earnings History.

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Syndax Pharmaceuticals.

7 Wall Street analysts have issued 1 year price targets for Syndax Pharmaceuticals' shares. Their predictions range from $20.00 to $40.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $26.1667 in the next year. View Analyst Ratings for Syndax Pharmaceuticals.

Syndax Pharmaceuticals saw a decrease in short interest in March. As of March 29th, there was short interest totalling 967,476 shares, a decrease of 42.3% from the March 15th total of 1,676,430 shares. Based on an average daily trading volume, of 352,354 shares, the days-to-cover ratio is currently 2.7 days. Approximately 5.6% of the shares of the company are sold short.

Some companies that are related to Syndax Pharmaceuticals include CytomX Therapeutics (CTMX), MacroGenics (MGNX), Biohaven Pharmaceutical (BHVN), Flexion Therapeutics (FLXN), Uniqure (QURE), Epizyme (EPZM), Amphastar Pharmaceuticals (AMPH), Inflarx (IFRX), Assembly Biosciences (ASMB), Alder BioPharmaceuticals (ALDR), Access Pharmaceuticals (ABEO), Lexicon Pharmaceuticals (LXRX), Eagle Pharmaceuticals (EGRX), Mirati Therapeutics (MRTX) and Vectura Group (VEGPF).

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Headlines about SNDX stock have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syndax Pharmaceuticals earned a coverage optimism score of 0.11 on Accern's scale. They also gave news headlines about the company an impact score of 47.08 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SNDX stock can currently be purchased for approximately $10.39.

Syndax Pharmaceuticals has a market capitalization of $253.15 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]